TG Therapeutics, Inc.
COMBINATION OF AN ANTI-CD20 ANTIBODY, PI3 KINASE-DELTA INHIBITOR, AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY FOR TREATING HEMATOLOGICAL CANCERS

Abstract:

The present disclosure provides methods and kits for treating or slowing the progression of a hematological malignancy, by administering to a subject in need thereof a therapeutically effective amount of: (i) at least one inhibitor of PI3 kinase (PI3K)-delta (e.g., TGR-1202); (ii) at least one anti-CD20 antibody (e.g., ublituximab); and (iii) at least one anti-PD-1 antibody (e.g., pembrolizumab) or anti-PD-Ll antibody (e.g., atezolizumab). Treatment regimens are also provided.